A new study presented at the American Society of Clinical Oncology (ASCO) annual meeting showed that Belzutifan treatment of VHL-related tumors durably shrinks tumors and may reduce the number of surgeries needed in patients with cancers associated with a von Hippel-Lindau (VHL) gene deletion or mutation. Five-year follow-up findings showed the following response rates: Learn …
Permanent link to this article: https://inheritedcancer.net/post080525/
On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at ๐https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769
Permanent link to this article: https://inheritedcancer.net/post121021/
